MMP-9 expression in peripheral blood mononuclear cells and the association with clinicopathological features and prognosis of nasopharyngeal carcinoma

被引:9
作者
He, Jian-Rong [1 ,2 ]
Qin, Han [1 ,2 ]
Ren, Ze-Feng [1 ,2 ]
Cui, Cui [2 ,3 ]
Zhang, Ying [2 ,3 ]
Ranatunga, Dharshana [1 ,2 ]
Zeng, Yi-Xin [2 ,3 ]
Jia, Wei-Hua [1 ,2 ,3 ]
机构
[1] Sun Yat Sen Univ, Sch Publ Hlth, Guangzhou 510080, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol S China, Guangzhou 510080, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Ctr Canc, Dept Expt Res, Guangzhou 510080, Guangdong, Peoples R China
关键词
matrix metalloproteinase-9; mRNA expression; nasopharyngeal carcinoma; peripheral blood mononuclear cells; prognosis; EPSTEIN-BARR-VIRUS; MESSENGER-RNA EXPRESSION; MEMBRANE-PROTEIN; SERUM MATRIX-METALLOPROTEINASE-9; CLINICAL-SIGNIFICANCE; TISSUE INHIBITOR; CANCER; METALLOPROTEINASE-9; NEUTROPHILS; HEAD;
D O I
10.1515/CCLM.2011.095
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Matrix metalloproteinase-9 (MMP-9) shows significant involvement with cancer invasion and therefore has prognostic significance. Tumor tissues from nasopharyngeal carcinoma (NPC) patients are not easy to access, and peripheral blood mononuclear cells (PBMC) are a valuable alternative. This study compared the expression levels of MMP-9 in PBMCs from NPC patients and healthy controls and evaluated the potential as a prognostic biomarker for NPC patients. Methods: MMP-9 mRNA concentrations in PBMCs from 146 NPC patients and 110 healthy controls were measured using quantitative real-time PCR. Differences in MMP-9 expression between NPC patients and controls were evaluated using non-parametric tests, and the effects of different clinical characteristics on MMP-9 expression were also analyzed. The Kaplan-Meier test and Cox regression model were used to explore the association between MMP-9 expression and overall survival of NPC patients. Results: MMP-9 mRNA levels in PBMCs were significantly higher in NPC patients than in healthy controls (p < 0.001). Increased MMP-9 expression was associated with the following clinical characteristics: advanced clinical stage (p < 0.001), T stage (p=0.016), N stage (p=0.002), histology type (p=0.037), and poor overall survival (p=0.049). Conclusions: MMP-9 mRNA expression in PBMCs from NPC patients is increased and associated with the clinical characteristics and overall survival. It supports the belief that MMP-9 may contribute to the progression of NPC.
引用
收藏
页码:705 / 710
页数:6
相关论文
共 48 条
[1]   Soluble interleukin-2 receptor and metalloproteinase-9 expression in head and neck cancer: prognostic value and analysis of their relationships [J].
Agueznay, N. El Houda ;
Badoual, C. ;
Hans, S. ;
Gey, A. ;
Vingert, B. ;
Peyrard, S. ;
Quintin-Colonna, F. ;
Ravel, P. ;
Bruneval, P. ;
Roncelin, S. ;
Lelongt, B. ;
Bertoglio, J. ;
Fridman, W. H. ;
Brasnu, D. ;
Tartour, E. .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2007, 150 (01) :114-123
[2]   Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis [J].
Ardi, Veronica C. ;
Kupriyanova, Tatyana A. ;
Deryugina, Elena I. ;
Quigley, James P. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (51) :20262-20267
[3]   Neutrophil MMP-9 Proenzyme, Unencumbered by TIMP-1, Undergoes Efficient Activation in Vivo and Catalytically Induces Angiogenesis via a Basic Fibroblast Growth Factor (FGF-2)/FGFR-2 Pathway [J].
Ardi, Veronica C. ;
Van den Steen, Philippe E. ;
Opdenakker, Ghislain ;
Schweighofer, Bernhard ;
Deryugina, Elena I. ;
Quigley, James P. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (38) :25854-25866
[4]   MMP-9 (Gelatinase B) Expression is Associated With Disease-Free Survival and Disease-Specific Survival in Colorectal Cancer Patients [J].
Bendardaf, Riyad ;
Buhmeida, Abdelbaset ;
Hilska, Marja ;
Laato, Matti ;
Syrjanen, Stina ;
Syrjanen, Kari ;
Collan, Yrjo ;
Pyrhonen, Seppo .
CANCER INVESTIGATION, 2010, 28 (01) :38-43
[5]   A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells [J].
Black, RA ;
Rauch, CT ;
Kozlosky, CJ ;
Peschon, JJ ;
Slack, JL ;
Wolfson, MF ;
Castner, BJ ;
Stocking, KL ;
Reddy, P ;
Srinivasan, S ;
Nelson, N ;
Boiani, N ;
Schooley, KA ;
Gerhart, M ;
Davis, R ;
Fitzner, JN ;
Johnson, RS ;
Paxton, RJ ;
March, CJ ;
Cerretti, DP .
NATURE, 1997, 385 (6618) :729-733
[6]   Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies [J].
Buergy, Daniel ;
Weber, Theresia ;
Maurer, Gabriele D. ;
Mudduluru, Giridhar ;
Medved, Fabian ;
Leupold, Joerg H. ;
Brauckhoff, Michael ;
Post, Stefan ;
Dralle, Henning ;
Allgayer, Heike .
INTERNATIONAL JOURNAL OF CANCER, 2009, 125 (04) :894-901
[7]   Prognostic significance of matrix metalloproteinase-9 (MMP-9) in stage II colorectal carcinoma [J].
Buhmeida A. ;
Bendardaf R. ;
Hilska M. ;
Collan Y. ;
Laato M. ;
Syrjänen S. ;
Syrjänen K. ;
Pyrhönen S. .
Journal of Gastrointestinal Cancer, 2009, 40 (3-4) :91-97
[8]   Transcriptional profiling of peripheral blood cells in clinical pharmacogenomic studies [J].
Burczynski, ME ;
Dorner, AJ .
PHARMACOGENOMICS, 2006, 7 (02) :187-202
[9]   Blood gene expression signatures predict exposure levels [J].
Bushel, P. R. ;
Heinloth, A. N. ;
Li, J. ;
Huang, L. ;
Chou, J. W. ;
Boorman, G. A. ;
Malarkey, D. E. ;
Houle, C. D. ;
Ward, S. M. ;
Wilson, R. E. ;
Fannin, R. D. ;
Russo, M. W. ;
Watkins, P. B. ;
Tennant, R. W. ;
Paules, R. S. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (46) :18211-18216
[10]  
Chen ZY, 2009, J NEUROTRAUM, V26, pA60